DDInter1762 DDInter178
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Temozolomide {u} (Compound) treats {v} (Disease) brain cancer
Temozolomide {u} (Compound) binds {v} (Gene) CYP3A4
Temozolomide {u} (Compound) upregulates {v} (Gene) CAPN1
Temozolomide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Temozolomide {u} (Compound) downregulates {v} (Gene) ATP6V1D
Temozolomide {u} (Compound) causes {v} (Side Effect) Constipation
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluorouracil
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Temozolomide (Compound) treats brain cancer (Disease)
Temozolomide (Compound) binds CYP3A4 (Gene)
Temozolomide (Compound) upregulates CAPN1 (Gene)
Temozolomide (Compound) is included by Alkylating Activity (Pharmacologic Class)
Temozolomide (Compound) downregulates ATP6V1D (Gene)
Temozolomide (Compound) causes Constipation (Side Effect)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab